Muhammad Umar Jawad1, Brad H Pollock2, Barton L Wise1,3, Lauren N Zeitlinger1, Edmond F O' Donnell1, Janai R Carr-Ascher1,3, Amy Cizik4, Betty Ferrell5, Steven W Thorpe1, R Lor Randall1. 1. Department of Orthopaedic Surgery, UC Davis School of Medicine, Sacramento, California, USA. 2. Department of Public Health Sciences, UC Davis School of Medicine, Sacramento, California, USA. 3. Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California, USA. 4. Department of Orthopaedic Surgery, University of Utah, Salt Lake City, Utah, USA. 5. Department of Nursing and Palliative Care, City of Hope, Duarte, California, USA.
Abstract
BACKGROUND: We have analyzed sex, race/ethnicity or socioeconomic disparities in the incidence of metastatic bone disease (MBD). METHODS: Patients with the diagnosis of MBD at presentation for five most common primary anatomical sites was extracted from Surveillance, Epidemiology, and End Results Census tract-level dataset. Mean incidence of MBD for different sex, racial/ethnic and socioeconomic groups were compared. RESULTS: The five most common anatomical sites with MBD at presentation include "lung: (n = 59 739), "prostate" (n = 19 732), "breast" (n = 16 244), "renal" (n = 7718) and "colon" (n = 3068). There was an increase in incidence of MBD among cancers originating from prostate (annual percentage change [APC] 4.94), renal (APC 2.55), and colon (APC 3.21) (p < 0.05 for all). Non-Hispanic Blacks had higher incidence of MBD for prostate and breast primary sites (p < 0.001). Non-Hispanic American Indian Alaskan Native had higher incidence of MBD for cancers originating from renal (p < 0.001) and colon (p = 0.049). A higher incidence of MBD was seen in lower socioeconomic status (SES) groups for the selected sites (p < 0.001). CONCLUSIONS: These findings suggest that there are multiple sex-related, racial/ethnic and SES disparities in the incidence of MBD from the 5 most common primary sites. Higher incidence seen among lower SES suggests delay in diagnosis and limited access to screening modalities.
BACKGROUND: We have analyzed sex, race/ethnicity or socioeconomic disparities in the incidence of metastatic bone disease (MBD). METHODS: Patients with the diagnosis of MBD at presentation for five most common primary anatomical sites was extracted from Surveillance, Epidemiology, and End Results Census tract-level dataset. Mean incidence of MBD for different sex, racial/ethnic and socioeconomic groups were compared. RESULTS: The five most common anatomical sites with MBD at presentation include "lung: (n = 59 739), "prostate" (n = 19 732), "breast" (n = 16 244), "renal" (n = 7718) and "colon" (n = 3068). There was an increase in incidence of MBD among cancers originating from prostate (annual percentage change [APC] 4.94), renal (APC 2.55), and colon (APC 3.21) (p < 0.05 for all). Non-Hispanic Blacks had higher incidence of MBD for prostate and breast primary sites (p < 0.001). Non-Hispanic American Indian Alaskan Native had higher incidence of MBD for cancers originating from renal (p < 0.001) and colon (p = 0.049). A higher incidence of MBD was seen in lower socioeconomic status (SES) groups for the selected sites (p < 0.001). CONCLUSIONS: These findings suggest that there are multiple sex-related, racial/ethnic and SES disparities in the incidence of MBD from the 5 most common primary sites. Higher incidence seen among lower SES suggests delay in diagnosis and limited access to screening modalities.
Authors: Carol E DeSantis; Jiemin Ma; Mia M Gaudet; Lisa A Newman; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-10-02 Impact factor: 508.702
Authors: Elien Van der Gucht; Lore Dams; Mira Meeus; Nele Devoogdt; Annemarie Beintema; Frauke Penen; Wouter Hoelen; Tessa De Vrieze; An De Groef Journal: Support Care Cancer Date: 2020-01-17 Impact factor: 3.603
Authors: Clement G Yedjou; Jennifer N Sims; Lucio Miele; Felicite Noubissi; Leroy Lowe; Duber D Fonseca; Richard A Alo; Marinelle Payton; Paul B Tchounwou Journal: Adv Exp Med Biol Date: 2019 Impact factor: 2.622